Put Options

15 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$460.0 - $505.78 $2.71 Million - $2.98 Million
-5,900 Reduced 31.55%
12,800 $5.95 Million
Q2 2024

Aug 14, 2024

SELL
$392.81 - $485.53 $8.96 Million - $11.1 Million
-22,800 Reduced 54.94%
18,700 $8.77 Million
Q1 2024

May 15, 2024

BUY
$407.69 - $446.08 $13 Million - $14.2 Million
31,900 Added 332.29%
41,500 $17.3 Million
Q4 2023

Feb 14, 2024

SELL
$343.0 - $410.68 $15.4 Million - $18.4 Million
-44,800 Reduced 82.35%
9,600 $3.91 Million
Q3 2023

Nov 14, 2023

BUY
$338.18 - $362.46 $17 Million - $18.3 Million
50,400 Added 1260.0%
54,400 $18.9 Million
Q2 2023

Aug 14, 2023

SELL
$314.42 - $351.91 $754,608 - $844,584
-2,400 Reduced 37.5%
4,000 $1.41 Million
Q1 2023

May 15, 2023

BUY
$283.23 - $323.1 $169,938 - $193,860
600 Added 10.34%
6,400 $2.02 Million
Q4 2022

Feb 14, 2023

BUY
$285.76 - $321.48 $57,152 - $64,296
200 Added 3.57%
5,800 $1.67 Million
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $1.53 Million - $1.71 Million
5,600 New
5,600 $1.62 Million
Q2 2020

Aug 14, 2020

SELL
$225.48 - $295.8 $428,412 - $562,020
-1,900 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$199.77 - $247.81 $2.3 Million - $2.85 Million
-11,500 Reduced 85.82%
1,900 $452,000
Q4 2019

Feb 14, 2020

BUY
$166.71 - $223.91 $616,827 - $828,467
3,700 Added 38.14%
13,400 $2.93 Million
Q3 2019

Nov 14, 2019

BUY
$166.23 - $187.09 $448,821 - $505,143
2,700 Added 38.57%
9,700 $1.64 Million
Q2 2019

Aug 14, 2019

BUY
$164.61 - $190.37 $1.02 Million - $1.18 Million
6,200 Added 775.0%
7,000 $1.28 Million
Q1 2019

May 15, 2019

BUY
$163.73 - $194.7 $130,983 - $155,760
800 New
800 $147,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.